The journey begins in New York, where Founder and Chief Executive Officer Dr. Alex Zhavoronkov will attend the Morgan Stanley 24th Annual Global Healthcare Conference from September 14 to 16. On September 15 at 14:35, Zhavoronkov is scheduled to participate in an in-person fireside chat, engaging global investors and industry leaders on the company’s latest advances in generative AI-driven drug discovery, aging clocks and anti-aging interventions. The Morgan Stanley conference is widely regarded as one of the largest and most influential healthcare investment gatherings in the world, convening thousands of leaders each year, from multinational pharmaceutical companies and biotech innovators to medical device makers, digital health pioneers, hedge funds, long-only investors, consulting firms and regulatory bodies. Its mix of keynote addresses, fireside chats, one-on-one investor meetings and forward-looking roundtables makes it a core venue where international capital identifies healthcare opportunities and where large pharmaceutical companies scout innovative technologies and potential acquisition targets.

For Zhavoronkov, the New York appearance is an opportunity to present Insilico’s progress to the capital markets at a moment of unusual momentum. The company has been steadily expanding its narrative beyond a single headline asset, highlighting an end-to-end autonomous laboratory roadmap that pairs its generative chemistry platforms with laboratory automation designed to compress the timelines of target identification, molecular design and preclinical validation. The aging research dimension of the company’s work, including its well-known deep learning aging clocks that estimate biological age from multimodal data, has long differentiated Insilico from AI drug discovery peers, and executives are expected to weave that longevity science perspective into their dialogue with investors who increasingly view aging biology as a fertile ground for new therapeutics.

From New York the focus shifts to the Middle East. Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to the Riyadh Global Medical Biotechnology Summit, known as RGMBS 2026, running September 14 to 16 in the Saudi capital. On September 16, from 09:00 to 12:00 at the Sofitel Riyadh Hotel and Convention Center, Aliper will lead the Insilico team in hosting a hands-on workshop titled Model Context Protocol-Empowered Protein Design: Combining AI Foundation Models and Physics-Based Molecular Modelling. The session is designed to be intensely practical. Participants will gain first-hand experience using the Model Context Protocol, or MCP, to connect AI foundation models, molecular simulation engines and chemical databases. The curriculum covers the complete workflow from protein and ligand structure preparation through physics-based validation, teaching attendees how to score and prioritize drug candidates with AlphaFold, RDKit and OpenMM, how to interpret binding modes, kinetics and free-energy calculation results, and how to run a directed MCP workflow inside Insilico’s Chemistry42 sandbox environment.

The choice of technical material is significant. The Model Context Protocol has emerged as an open standard for connecting large AI models with external tools and data sources, and Insilico’s workshop represents one of the most concrete demonstrations of how that architecture can be applied to protein engineering and small-molecule discovery. By linking generative foundation models to physics-based simulation, the workflow aims to marry the speed and creativity of deep learning with the rigor of molecular mechanics, free-energy perturbation and kinetics analysis that medicinal chemists have long demanded. Aliper, who has spent much of his career at the intersection of AI-driven drug discovery, frontier biomedical science and cross-disciplinary tool integration, will also use the summit to showcase Insilico’s role in building the Chemistry42 generative chemistry platform and the company’s broader autonomous laboratory ecosystem, positioning the workshop as a window into how modern AI-native biopharma companies orchestrate computational and experimental workflows.

RGMBS 2026 itself carries strategic weight. Co-initiated by the Saudi Ministry of Health, the Royal Commission for Riyadh City and leading biomedical authorities, the summit is one of the largest international biotechnology and medical innovation gatherings in the Middle East. It convenes scientists, research and development leaders, clinical experts, regulators and strategic investors spanning biopharmaceuticals, gene and cell therapy, medical devices, digital health and fundamental life sciences. Organizers have centered the program on frontier biotechnology, precision medicine, AI-driven drug discovery, translational medicine, health-tech investment and biomanufacturing, using keynote addresses, themed workshops, closed-door sessions, industry matchmaking and project roadshows to drive cross-regional collaboration. For global biopharma companies, the event is increasingly viewed as a gateway to the Middle East market and to Saudi Vision 2030, the kingdom’s national strategy that places biomedical capability among its economic diversification priorities.

The third stop brings Insilico to Shanghai, where Co-CEO and Chief Scientific Officer Dr. Feng Ren will attend Bio-Shanghai Week 2026, an event anchored by Zhangjiang Drug Valley, a national-level biopharmaceutical industry hub. On September 17 at 15:00, during the opening ceremony’s AI-Driven Innovation session, Ren will engage in an in-depth dialogue with Professor Michael Levitt, the 2013 Nobel Laureate in Chemistry and Stanford University structural biology professor, on the theme of AI-driven global innovation in therapeutic target discovery and treatment technologies. The conversation is expected to traverse three dimensions: foundational science breakthroughs, industrial translation pathways and global strategic coordination, examining how artificial intelligence is systematically reshaping the full chain from target discovery through molecular design to clinical development. Ren, regarded as one of the leading scientists driving AI-enabled drug research and clinical translation in China, will share Insilico’s generative AI platform, its pipeline progress and the company’s global footprint, creating what organizers describe as a high-level exchange between a leading Chinese AI-driven pharmaceutical company and a top global scientist.

Bio-Shanghai Week ranks among the largest and most internationally influential biopharmaceutical industry events in Shanghai, drawing leading scientists, clinical experts, multinational pharmaceutical and biotech companies, innovative drug and device developers, investors, regulators and industry service platforms. Its agenda spans AI-driven innovation, gene and cell therapy, antibodies and antibody-drug conjugates, rare diseases, neuroscience, global market access, clinical translation and the broader industry ecosystem. The event serves as a vital window into the frontier of China’s biopharmaceutical industry and the wider Yangtze River Delta innovation ecosystem, a region that has become one of the world’s densest concentrations of drug discovery talent and capital.

The final leg of the tour takes Zhavoronkov to Boston on September 18 for the Harvard IvyTech Discussion, co-initiated by Harvard University and other Ivy League academic institutions. From 10:50 to 12:00, he will deliver a keynote address in a forum titled A Geo-Economic Shift: China’s Rise as an Innovation Powerhouse in Biotech. Sharing the stage with leading scientists, industry strategists and policy researchers from North America’s top institutions, Zhavoronkov will discuss the leapfrog transformation of China’s biopharmaceutical industry from generic manufacturing to first-in-class innovation, and the corresponding evolution of the global biopharma value chain and capital landscape. He is also expected to present Insilico’s strategic blueprint as what the company calls a bridge enterprise connecting Eastern and Western innovation ecosystems, spanning Chinese foundational research, the company’s AI platform technology, its global research and development pipeline, and its international capital and industry partnerships. The IvyTech platform, which focuses on frontier technology, industrial transformation and geo-economic topics, brings together scientists, technology executives, entrepreneurs, policymakers and institutional investors for dialogue across biomedical innovation, artificial intelligence, advanced manufacturing, the energy transition and cross-border innovation ecosystems.

The speaking tour arrives at a pivotal financial and scientific moment for Insilico Medicine. The company recently reported total revenue of approximately 106 million US dollars in the first half of 2026, a 287 percent year-over-year increase, and achieved its first profitable half-year since listing, with adjusted net profit exceeding 51 million dollars. The milestone was driven by a series of out-licensing, co-development and research collaborations with global partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS and Tenacia. As of the latest practicable date, the total contract value of transactions announced by the company in 2026 reached approximately 7.3 billion dollars, pushing the cumulative contract value of its major collaborations since 2021 to roughly 11 billion dollars. On the research front, Insilico nominated nine development candidates within the first nine months of 2026 as of late August, a company record for annual pipeline productivity, and achieved eight clinical milestones across its proprietary and co-developed programs. Leading that progress is rentosertib, also known as ISM001-055, the world’s first drug candidate discovered and developed using generative AI, which has advanced into a Phase III trial evaluating treatment for idiopathic pulmonary fibrosis, a progressive and often fatal scarring lung disease with few therapeutic options. Listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 under the stock code 03696.HK, Insilico continues to apply its Pharma.AI platform to fibrosis, oncology, immunology, pain, obesity and metabolic disorders, while extending the technology into advanced materials, agriculture, nutritional products and veterinary medicine. The four-city executive tour, spanning capital markets in New York, biotechnology diplomacy in Riyadh, scientific dialogue in Shanghai and academic strategy in Boston, functions as a compressed portrait of the company’s thesis: that generative AI, rigorous physics-based validation and global collaboration can deliver better drugs faster, and that the companies able to bridge the world’s major innovation hubs will define the next decade of biopharmaceutical progress.

Subject of Research: Insilico Medicine executive participation in four global healthcare and AI summits showcasing generative AI drug discovery

Article Title: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits

Article References: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Insilico Medicine, generative AI, drug discovery, rentosertib, AlphaFold, Model Context Protocol, aging clocks, biotechnology, idiopathic pulmonary fibrosis, AI summits, autonomous laboratory, biopharmaceutical innovation

The biological rationale behind the study rests on one of glioblastoma’s most distinctive metabolic vulnerabilities. Unlike many tissues that synthesize their own cholesterol, glioblastoma cells are heavily co-dependent on exogenous cholesterol to fuel oncogenic signaling and the relentless membrane biogenesis required for rapid proliferation. This dependency places the liver X receptor beta (LXRβ), the principal transcriptional regulator of cholesterol efflux in the central nervous system, at the center of a promising therapeutic strategy. Activating LXRβ in tumor cells forces them to export cholesterol, depleting intracellular pools and effectively starving the cancer of a raw material it cannot easily replace.

The catch has always been selectivity. LXR receptors come in two flavors, LXRα and LXRβ, and indiscriminate activation of both has historically caused hepatotoxicity through excessive lipogenesis in the liver, where LXRα dominates. Early synthetic agonists such as T-0901317 activated both isoforms and were never suitable for chronic cancer therapy. On top of that, any drug aimed at a brain tumor must cross the blood-brain barrier, a formidable filter that excludes most large or polar molecules. Developing an LXRβ-selective, brain-penetrant agonist has therefore remained an unsolved challenge in neuro-oncology, and it is precisely the problem the Chinese team set out to crack with machine learning rather than traditional medicinal chemistry.

Their solution is a multi-layered computational pipeline that combines several complementary artificial intelligence approaches. At its core sits a machine learning-based quantitative structure-activity relationship (QSAR) model trained to predict LXRβ binding affinity, working alongside a directed message passing neural network (D-MPNN), a graph-based deep learning architecture that learns molecular representations directly from chemical structure. A deep learning-based drug-target interaction (DTI) predictor adds a third independent estimate of whether a given compound is likely to engage the receptor. By running a curated library of approximately 1.2 million natural products through this ensemble, the team could rank candidates not just on raw predicted potency but on the probability that the predictions would hold up experimentally.

Crucially, the pipeline did not stop at affinity. The researchers applied sequential filters for LXRβ/LXRα selectivity, ensuring that hits would preferentially activate the beta isoform and spare the liver from unwanted LXRα-driven lipogenesis. An integrated pharmacokinetic scoring step then assessed whether candidates possessed the physicochemical properties needed to reach the brain. Surviving compounds were subjected to molecular docking and MM-GBSA binding free energy calculations, which model the physical fit and energetics of each ligand inside the LXRβ binding pocket. This layered funnel, from millions of compounds down to a handful of high-confidence candidates, exemplifies how modern AI screening can compress what was once a decade-long campaign into a focused computational exercise.

Four candidates emerged from the computational gauntlet, and the team moved to the laboratory to test them. Using CCK-8 cytotoxicity assays across five glioblastoma cell lines and six normal cell models, the researchers evaluated both anti-tumor potency and therapeutic window. One compound stood out: 5,6-epoxyergosterol, an oxidized derivative of ergosterol, the fungal counterpart of cholesterol. The molecule showed potent cytotoxicity against glioma cells while sparing normal cells, exactly the selectivity profile the computational filters were designed to enforce. That a compound derived from fungal sterols, a chemical class evolutionarily tuned to interact with sterol-sensing proteins, would emerge as an LXRβ agonist is a satisfying convergence of natural product chemistry and computational prediction.

To understand how 5,6-epoxyergosterol engages its target at atomic resolution, the team ran a 200-nanosecond molecular dynamics simulation of the LXRβ-ligand complex. The simulation demonstrated remarkably stable binding throughout the trajectory, with the compound anchored by dominant hydrogen-bonding contacts to two key residues, His435 and Trp443, in the receptor’s ligand-binding domain. The free energy landscape computed from the simulation was consistent with a single dominant agonist-bound conformation, suggesting that the compound locks the receptor into an active state rather than sampling multiple binding modes. This kind of conformational stability is what medicinal chemists look for when distinguishing genuine agonists from transient binders, and it provides a structural hypothesis for how the fungal sterol activates cholesterol efflux genes.

The broader significance of the work extends beyond a single compound. The study draws on rich genomic datasets to justify its target: single-cell RNA sequencing data from 24 IDH-wildtype glioblastoma tumors comprising 7,550 cells, bulk RNA-seq data from 173 patients in the TCGA-GBM cohort, and spatial transcriptomics from the Ivy Glioblastoma Atlas Project. By grounding the computational campaign in human tumor data, the researchers ensured that the cholesterol dependency they were exploiting is not an artifact of cell culture but a feature of real disease. The approach also positions fungal natural products, an underexplored corner of chemical space compared with plant-derived compounds, as a rich source of central nervous system drug leads.

For a field that has seen no new approved systemic therapy in more than ten years, the prospect of a cholesterol-starvation strategy delivered by a brain-penetrant, LXRβ-selective natural product is genuinely exciting. The standard of care remains surgical resection followed by radiotherapy and temozolomide chemotherapy, with median survival measured in months, and recent immunotherapy and targeted therapy efforts have largely failed to move the needle. Metabolic vulnerabilities like the LXR-cholesterol axis offer a way to attack the tumor’s fundamental biochemistry, an approach that may be harder for heterogeneous tumors to escape than single-pathway inhibition, since every glioblastoma cell needs membranes.

Considerable work remains before 5,6-epoxyergosterol or its analogs reach the clinic. The current evidence rests on computational prediction, in vitro cytotoxicity, and simulation; animal pharmacokinetics, brain exposure studies, and formal selectivity profiling against the full nuclear receptor family will be essential next steps. Nevertheless, the study delivers a validated AI-driven framework for natural product drug discovery in neuro-oncology, one that other laboratories can adapt to different targets and compound libraries. If the fungal ergosterol derivatives identified here continue to perform as they move toward preclinical development, the marriage of machine learning and mycology may prove to be one of the more unexpected alliances in the fight against brain cancer.

Subject of Research: AI-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting cholesterol dependency in glioblastoma

Article Title: Artificial intelligence-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting the cholesterol dependency of glioblastoma

Article References: Li, Q., Zhang, C., Hu, T., Zhang, Z., & Wu, H. (2026). Artificial intelligence-guided discovery of fungal ergosterol derivatives as selective LXRβ agonists targeting the cholesterol dependency of glioblastoma. Molecular Diversity. https://doi.org/10.1007/s11030-026-11728-7

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11728-7

Keywords: glioblastoma, LXRβ, cholesterol metabolism, artificial intelligence, virtual screening, natural products, ergosterol, blood-brain barrier, molecular dynamics, drug discovery, neuro-oncology, machine learning

Aliper will first participate in the Global Unicorn Summit, scheduled for August 24–25, 2026, in Hong Kong, China. His panel, “What Will Power the Next Wave of Global Growth?”, will take place on August 24 from 15:00 to 15:50. The discussion is expected to examine how emerging technologies can generate measurable economic value, particularly as artificial intelligence becomes increasingly integrated into scientific research, industrial development, and international business strategy. As president of Insilico Medicine, Aliper is positioned to offer a perspective shaped by the company’s efforts to combine machine learning, biomedical data, and pharmaceutical development within a single technology platform.

Generative AI in drug discovery differs substantially from the consumer-facing systems that produce text, images, or software code. In biomedical research, generative models are trained on complex biological and chemical datasets, including molecular structures, gene-expression profiles, disease-associated pathways, protein information, and clinical observations. These systems can learn statistical relationships within the data and generate hypotheses about new drug targets, biomarkers, or molecular compounds. The objective is not simply to predict which molecules already exist, but to design candidates with specific characteristics, such as improved potency, selectivity, solubility, metabolic stability, and reduced toxicity.

Insilico Medicine has developed a proprietary generative AI platform intended to support multiple stages of the drug-discovery process. One component is designed to identify disease-relevant biological targets by analyzing diverse forms of biomedical evidence, while another can generate novel molecular structures aimed at interacting with those targets. Additional computational tools can be used to estimate pharmacological properties and prioritize candidates before they enter laboratory testing. This approach can reduce the number of compounds that must be synthesized and experimentally evaluated, although every AI-generated hypothesis still requires validation through biochemical studies, cellular experiments, animal models, and ultimately clinical trials.

At the Global Unicorn Summit, Aliper is expected to discuss how this combination of computational modeling and experimental science can translate technological innovation into industrial momentum. The central challenge for biotechnology companies is not merely building a powerful algorithm, but demonstrating that the algorithm improves decisions in the real world. A successful platform must help researchers identify more credible targets, generate stronger drug candidates, shorten development timelines, and produce evidence that can withstand regulatory and scientific scrutiny. The commercial significance of AI therefore depends on its ability to function as part of a reproducible research workflow rather than as a standalone software demonstration.

Insilico Medicine’s participation will also highlight the international character of modern drug development. A drug-discovery program may involve algorithm development in one country, biological research in another, clinical testing across several regions, and manufacturing or licensing partnerships in additional markets. This distributed structure makes collaboration between technology companies, pharmaceutical organizations, investors, research institutions, and governments increasingly important. The Global Unicorn Summit is designed to connect these groups across sectors, with sessions addressing artificial intelligence, biomedicine, new energy, advanced materials, fintech, robotics, smart vehicles, and semiconductors.

Aliper’s second major appearance will take place at MedTech World Asia, scheduled for August 26–28, also in Hong Kong. On August 27, he will deliver remarks and participate in the panel “AI & Precision Medicine: Turning Data into Targeted Care,” scheduled from 12:35 to 13:10. Precision medicine seeks to replace broad, population-level treatment strategies with approaches that account for differences among patients, including their genetic background, molecular disease characteristics, immune status, lifestyle, and response to previous therapies. Artificial intelligence can help analyze these variables by integrating datasets too large and complex for conventional manual methods.

In oncology and other disease areas, precision medicine depends on identifying biomarkers that reveal how a disease is likely to progress or how a patient may respond to a particular therapy. Biomarkers can include mutations, protein signatures, patterns of gene activity, imaging features, or measurable changes in the immune system. Machine-learning models can search for combinations of signals that are associated with disease subtypes or treatment outcomes. When these predictions are connected to drug-discovery systems, researchers may be able to design therapies for biologically defined patient groups rather than relying solely on symptoms or anatomical classifications.

The scientific promise is significant, but the practical obstacles are equally important. Biomedical datasets are often incomplete, unevenly distributed, and generated using different experimental methods. Patient records may contain missing values, inconsistent terminology, or hidden biases that cause an algorithm to perform well in one population but poorly in another. Models must therefore be tested across independent datasets and diverse patient groups. Researchers also need to distinguish correlation from causation: a molecular feature associated with a disease is not necessarily a valid therapeutic target. In precision medicine, computational predictions become meaningful only when they lead to reliable biological measurements and improved clinical decisions.

During the MedTech World Asia panel, Aliper is expected to draw on Insilico Medicine’s work in target discovery, biomarker identification, and clinical pipeline development. He will also address the industry challenges involved in moving AI systems from research laboratories into healthcare settings. These challenges include data governance, patient privacy, algorithmic transparency, regulatory oversight, intellectual-property protection, and the need for cooperation between technology developers and clinical experts. The future of AI-enabled medicine will depend not only on model accuracy, but also on whether physicians, patients, regulators, and pharmaceutical companies can understand and trust the systems guiding high-stakes decisions.

The Hong Kong program will continue on August 28, when Aliper is scheduled to attend a luncheon titled “Cross-Border Exit Architecture for Asian MedTech Companies,” from 12:45 to 13:45. The session is expected to focus on how medical-technology companies can expand internationally, attract investment, form strategic partnerships, and create viable pathways toward acquisition, public listing, or other forms of cross-border growth. For AI-driven biotechnology firms, these questions are closely connected to scientific progress because advanced drug programs require substantial long-term financing, specialized infrastructure, regulatory expertise, and access to clinical networks.

The two summits together illustrate a broader shift in the technology landscape. Artificial intelligence is no longer being discussed only as a tool for automating routine tasks; it is increasingly being evaluated as infrastructure for discovering medicines, interpreting biological systems, and organizing healthcare around molecular information. Generative models may eventually help scientists explore chemical and biological possibilities that would be difficult to investigate manually, but their impact will be determined by the quality of the evidence they generate and the speed with which that evidence can be tested. Aliper’s upcoming appearances in Hong Kong will place this transition under an international spotlight, linking the computational foundations of modern biology with the investment, regulatory, and industrial systems required to turn scientific predictions into treatments.

Subject of Research: Generative artificial intelligence, AI-driven drug discovery, precision medicine, biomarker identification, and medical-technology commercialization.

Article Title: Generative AI and Precision Medicine Take Center Stage at Hong Kong Technology and Healthcare Summits

Image Credits: Insilico Medicine

Keywords: Generative AI, artificial intelligence, drug discovery, precision medicine, biotechnology, biomarkers, pharmaceutical research, Insilico Medicine, Alex Aliper, MedTech World Asia, Global Unicorn Summit, Hong Kong, healthcare innovation

The Prix Galien was established in 1970 in honor of Galen, the ancient physician whose work helped shape the foundations of medical science and pharmacology. The international program now operates across more than 75 countries and recognizes advances that have the potential to transform human health. Unlike awards focused solely on a single scientific publication or laboratory discovery, the Prix Galien evaluates innovation in the broader context of medicine, including translational research, clinical development, technology, and patient impact. Insilico is nominated alongside companies such as Mammoth Biosciences, SandboxAQ, Iambic Therapeutics, Hemab Therapeutics, and Science Corporation, placing its AI-driven development model within a competitive field of emerging biotechnology ventures.

The nomination follows a year of major changes for Insilico. The company has advanced its lead internally discovered drug into Phase III clinical development, completed an initial public offering on the Main Board of the Hong Kong Stock Exchange under the ticker HKEX: 3696, and expanded the commercial use of its generative AI platform. Since its 2025 Prix Galien nomination, Insilico has also announced drug-discovery and out-licensing agreements with an aggregate potential value of approximately $10 billion. These agreements include a collaboration with Eli Lilly and Company valued at up to $2.75 billion, an agreement with SK Biopharmaceuticals valued at up to $2.5 billion, and a partnership with China Medical System Holdings Limited. The arrangements suggest that AI-based research platforms are increasingly being assessed not only as software products, but also as sources of commercially valuable therapeutic programs.

At the center of Insilico’s progress is rentosertib, also known as ISM001-055, a small-molecule inhibitor designed to block TNIK, or TRAF2- and NCK-interacting kinase. The compound is being developed for idiopathic pulmonary fibrosis, a progressive lung disease in which scar tissue accumulates in the pulmonary interstitium, gradually reducing the lungs’ ability to transfer oxygen. TNIK is involved in signaling pathways associated with fibrosis and cellular behavior, making it a potential therapeutic target for limiting disease progression. Rentosertib was created through Insilico’s Pharma.AI platform, which combines PandaOmics for target identification, Chemistry42 for generative molecular design, and InClinico for forecasting clinical development outcomes. Together, these systems are intended to connect biological data analysis, chemical synthesis planning, and clinical strategy in a single computational workflow.

In July 2026, Insilico initiated a prospective, randomized, 52-week global Phase III study of rentosertib in approximately 320 patients with idiopathic pulmonary fibrosis. The trial represents a decisive test of whether the compound’s effects observed in earlier development can translate into clinically meaningful outcomes in a larger and more diverse patient population. It also carries symbolic significance for the AI drug-discovery field: Insilico describes rentosertib as the first drug to reach pivotal-stage clinical development after both its novel biological target and molecular structure were identified using generative AI. The program received Breakthrough Therapy Designation from China’s Center for Drug Evaluation, a regulatory status intended to accelerate the development of medicines showing preliminary evidence of substantial improvement over available treatment options.

The Phase III program follows results from a Phase IIa clinical study published in Nature Medicine. In that trial, rentosertib produced dose-dependent changes in forced vital capacity, or FVC, a standard measure of how much air a person can forcibly exhale after taking a deep breath. After 12 weeks, patients receiving the highest tested dose experienced a mean FVC increase of 98.4 milliliters, while participants receiving placebo experienced a mean decline of 20.3 milliliters. Although short-term changes in FVC do not by themselves establish long-term efficacy or alter the standard of care, the difference provided a clinical signal supporting continued evaluation. In pulmonary fibrosis research, maintaining or improving lung function is particularly important because progressive loss of respiratory capacity is closely linked to worsening disability and mortality. The larger Phase III study will need to clarify the durability, statistical reliability, safety, and clinical significance of the observed effect.

Insilico’s broader approach was described in a separate study published in Nature Biotechnology, which detailed the path from target nomination to a preclinical candidate in less than 18 months. PandaOmics analyzes large biological datasets to prioritize disease-associated targets, potentially integrating information from genomic studies, scientific literature, and other molecular sources. Chemistry42 then generates and evaluates candidate structures according to properties such as target affinity, selectivity, physicochemical behavior, and synthetic accessibility. This is not simply a process of asking an algorithm to invent a molecule. Drug candidates must survive repeated cycles of computational prediction, medicinal chemistry, laboratory testing, pharmacology, toxicology, and formulation research. The value of generative AI lies in narrowing the search space and proposing chemically plausible options more rapidly than conventional approaches alone, while experimental science remains essential for determining whether those predictions hold true in living systems.

The company reports that its platform has supported more than 33 preclinical candidates across fibrosis, oncology, immunology, and other disease areas, with more than 13 programs receiving investigational new drug clearance. It also says that it works with 13 of the world’s 20 largest pharmaceutical companies, offering services and collaborations involving target discovery, generative chemistry, and clinical-development applications. Such numbers indicate that the commercial market for AI-enabled biotechnology is expanding, but they do not automatically prove that every computationally generated program will succeed. Drug development remains characterized by high attrition, and many compounds fail because of toxicity, inadequate exposure, insufficient efficacy, manufacturing challenges, or unexpected biological complexity. The ultimate test of Insilico’s model will therefore be the number of approved therapies and the benefits they deliver to patients, rather than the number of algorithms, partnerships, or preclinical candidates generated.

Alex Zhavoronkov, Insilico’s founder and chief executive, said the second consecutive nomination was meaningful because of the progress made by both the company and the field since its first recognition. He pointed to rentosertib’s transition into Phase III, the maturation of Insilico’s internal pipeline, and the company’s expanding pharmaceutical collaborations. The 2026 Prix Galien USA ceremony is scheduled for October 29 at the American Museum of Natural History in New York City. Whether Insilico ultimately receives the award, its nomination highlights a pivotal moment in biotechnology: generative AI is no longer being judged solely by the novelty of its predictions, but by its ability to produce drug candidates that withstand the increasingly rigorous sequence of biological experiments, human trials, regulatory review, and real-world medical use. For patients living with idiopathic pulmonary fibrosis, the most consequential outcome will be whether rentosertib can safely preserve lung function and slow disease progression where existing treatments remain limited.

Subject of Research: Generative artificial intelligence-driven drug discovery and the development of rentosertib (ISM001-055), a TNIK inhibitor for idiopathic pulmonary fibrosis.

Article Title: Insilico Medicine Nominated for 2026 Prix Galien USA Award as AI-Discovered Drug Enters Phase III

News Publication Date: August 18, 2026

Web References: https://www.insilico.com; https://mediasvc.eurekalert.org/Api/v1/Multimedia/82069734-aa61-4580-9b03-443164f9a57d/Rendition/low-res/Content/Public

References: Galien Foundation and Prix Galien USA; Nature Medicine study reporting Phase IIa rentosertib results; Nature Biotechnology study describing Insilico’s AI-enabled drug-discovery process.

Image Credits: Prix Galien, Insilico Medicine

Keywords: Insilico Medicine, generative AI, artificial intelligence, drug discovery, rentosertib, ISM001-055, TNIK inhibitor, idiopathic pulmonary fibrosis, Phase III clinical trial, biotechnology, Pharma.AI, PandaOmics, Chemistry42, InClinico, Prix Galien USA, pharmaceutical innovation

At CPIC 2026, both executives are slated to deliver keynote-level insights during high-profile forums focused on global R&D progress and commercialization pathways for innovative therapeutics. Their presentations highlight how modern AI systems are shifting from experimental tools to operational platforms that can compress timelines across multiple stages of pharmaceutical development.

On July 23, Dr. Zhavoronkov will address AI-driven drug discovery from a global perspective and outline Insilico’s differentiated approach to overcoming persistent industry bottlenecks. His talk emphasizes a tightly integrated workflow built around the end-to-end Pharma.AI platform, designed to support iterative discovery, prioritization, and translation tasks while reducing friction between computational outputs and actionable experimental plans.

He will also describe the MMAI Gym, a specialized training and benchmarking framework intended to standardize model evaluation and improve performance under discovery-relevant constraints. By treating learning as a measured cycle—rather than a one-off optimization—MMAI Gym aims to raise reliability when models move from offline development into decisions that impact downstream chemistry and biology work.

Dr. Zhavoronkov will further focus on Insilico’s fully automated Robotic Chemistry and Biology Laboratory. The system represents a closed-loop validation strategy, where automated experimentation can rapidly test generated hypotheses and feed results back into the next iteration, strengthening the link between algorithmic design and clinical intent.

Later that day, Dr. Feng Ren will discuss Insilico’s blueprint for “source innovation” in AI drug discovery. His session will cover the spectrum from intelligent target identification to disruptive de novo molecular generation, illustrating how problem formulation and representation can shape downstream feasibility.

Ren will also explain how AI agent technologies are being integrated across the R&D pipeline, enabling more autonomous, workflow-aware decision-making. The goal is to use AI as a catalyst for discovery boundaries—translating scientific advances into a pipeline that can adapt as new evidence emerges.

Together, these talks position CPIC 2026 as a timely stage for viral science news: a moment when AI-driven discovery is increasingly framed not as a single breakthrough, but as an engineered capability that can be executed, benchmarked, and validated at scale.

Subject of Research: AI-driven drug discovery; pharmaceutical R&D automation; closed-loop validation
Article Title: Insilico Medicine Leaders to Speak at CPIC 2026 on AI-Driven Drug R&D and Closed-Loop Validation
News Publication Date:
Web References:
References:
Image Credits: Insilico Medicine

Keywords: AI-driven drug discovery, generative AI, RoboLab automation, closed-loop validation, Pharma.AI, MMAI Gym, AI agents, target identification, de novo molecular generation, CPIC 2026

At the core of the alliance is Insilico’s Pharma.AI platform, designed to support target discovery, generative chemistry, and molecule optimization. The company positions this as an integrated workflow that can translate novel molecular ideas into development-ready candidates more efficiently than conventional early-stage pipelines. Bora’s role centers on turning AI hypotheses into scalable, manufacturable programs with the quality and regulatory rigor demanded by global markets.

Both companies describe the partnership as an attempt to pioneer a “next-generation drug innovation model” that links AI-enabled design with automation-driven execution across the drug value chain. The press release emphasizes that this is not only about adding AI to existing steps, but reimagining how medicines are developed and delivered—combining data-rich decision-making with automated processes during development planning, process optimization, and manufacturing readiness.

The companies also propose training and organizational enablement components. Insilico expects to support Bora in strengthening AI capabilities across its workforce and improving AI literacy. In parallel, the alliance is expected to apply Insilico’s AI capabilities to improve efficiency in manufacturing operations, supply chain and distribution workflows, and corporate processes.

Insilico frames its productivity using timing metrics from its preclinical pipeline. It claims traditional preclinical discovery can take 2.5 to 4 years, while Insilico has reached preclinical candidate nomination in roughly 12 to 18 months on average. Since 2021, it reports nominating 31 preclinical candidates, with 13 receiving IND approval or clearance, and indicates the partnership aims to align this speed with Bora’s scale-up and development capacity.

As the alliance progresses, the parties expect to refine the collaboration’s scope and operating framework. They describe their shared vision as AI-native and automation-driven biopharmaceutical innovation—where value creation extends beyond molecular discovery to smarter translation into development programs and ultimately patient medicines.

Insilico also highlights its broader AI research direction through MMAI Gym, described as a “trainer and benchmark” environment integrating scientific reasoning with real-world evaluations. The company notes collaborations with Human Longevity and Liquid AI as partners of MMAI Gym, positioning this effort as part of a longer-term path toward robust scientific AI.

Subject of Research: Generative AI–driven drug discovery and development; AI-enabled pharmaceutical manufacturing and quality execution
Article Title: Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
News Publication Date: July 15, 2026
Web References: https://www.insilico.com ; https://www.bora-corp.com
References: Press release text provided in the prompt
Image Credits: Insilico Medicine
Keywords: generative AI, Pharma.AI, AI-native drug discovery, molecule optimization, preclinical candidates, CDMO, manufacturing automation, quality systems, AI literacy

The event, taking place from July 15 to 19 at the Taipei Nangang Exhibition Center, will gather over 850 exhibitors from nearly 60 countries, emphasizing cutting-edge biopharmaceutical research, AI-driven healthcare solutions, and cross-border digital health innovations. Dr. Zhavoronkov’s participation in a panel discussion on July 16, focused on AI × Medicine: Reshaping the Future of Drug Discovery, further underscores his role as a thought leader in this transformative space.

Insilico Medicine has pioneered the integration of generative AI and automation in drug discovery, drastically compressing timelines from target identification to the nomination of development candidates. This accelerated pipeline not only enhances scientific productivity but also introduces a self-improving AI platform that benefits from continuous learning across diverse research programs. Dr. Zhavoronkov’s keynote will explore these core pillars of sustainability, spotlighting how rigorous benchmark-driven productivity, strategic portfolio management, and AI-powered innovation coalesce to build a robust biotech enterprise.

The talk also promises technical insights into the novel AI frameworks Insilico employs to target complex diseases such as fibrosis, oncology, immunology, and metabolic disorders. By leveraging deep learning algorithms and automation, Insilico’s platform optimizes molecular design and candidate screening, enabling rapid iteration and refinement that conventional methods cannot match.

BIO Asia-Taiwan 2026, themed “Asian Inspiration, Global Impact,” provides a dynamic platform fostering international collaboration among life science leaders, investors, and innovators. The event’s integration of business partnering sessions and exhibitions aims to accelerate the translation of AI-driven discoveries into tangible healthcare solutions, reinforcing the pivotal role of technology in future drug development.

Insilico Medicine, publicly listed on the Hong Kong Stock Exchange since December 2025 (HKEX:3696), exemplifies the next-generation biotech company. Their approach extends beyond pharmaceuticals, applying Pharma.AI technologies to sectors like advanced materials, agriculture, and veterinary medicine, broadening the impact of AI innovations across multiple industries.

As AI continues to disrupt traditional drug discovery paradigms, events like BIO Asia-Taiwan become crucial forums for knowledge exchange and partnership building. Dr. Zhavoronkov’s involvement highlights the growing importance of sustainability-driven biotech strategies powered by AI, signaling a promising future for longevity-focused therapeutics and beyond.

This convergence of AI and life sciences not only accelerates the pace of innovation but also redefines how companies sustain growth, adapt, and continually generate value in the fast-evolving biotech landscape.

Subject of Research: AI-driven drug discovery and sustainable longevity biotech companies
Article Title: Spotlighting Longevity and AI Drug Discovery: Insilico Medicine to Showcase at BIO Asia-Taiwan 2026
News Publication Date: Not specified
Web References: www.insilico.com
Image Credits: Insilico Medicine
Keywords: Longevity, Artificial Intelligence, Drug Discovery, Generative AI, Biotechnology, Automation, Pharma.AI, BIO Asia-Taiwan

Catalysts play an indispensable role in facilitating chemical reactions, often governing the efficiency and viability of synthetic routes. Precious metals like palladium dominate the field, serving as the workhorse in many catalytic processes essential for constructing carbon-nitrogen (C–N) bonds—a key framework found in a great many pharmaceutical agents. However, the dependence on such metals brings complications given their limited geographical availability, high cost, and volatile supply chains. As modern drug candidates increase in complexity, the synthesis challenges become even more acute, demanding smarter approaches.

Artificial intelligence (AI) has emerged as a promising tool to accelerate drug discovery by predicting reaction outcomes and designing synthetic routes. Yet, the AI revolution in chemistry faces a significant bottleneck: the scarcity of large, high-quality, and systematically generated datasets required to properly train predictive models. Unlike other fields where data abundance fuels machine learning advancements, chemistry suffers from fragmented and incomplete reaction data, impeding the development of robust AI systems that can generalize across diverse reaction conditions.

Addressing this critical gap, Timothy Cernak and his team at the University of Michigan College of Pharmacy have launched an unprecedented open-access initiative—an expansive database comprising over 50,000 meticulously designed chemistry experiments. This colossal dataset focuses on reactions that form carbon-nitrogen bonds, capturing the nuances of thousands of ligands, catalysts, and operating parameters. By curating a rich and uniform collection of reaction data, the project empowers AI algorithms and chemists alike to discern patterns and mechanistic insights previously obscured by the noise of inconsistent reporting.

The University of Michigan’s database stands as the largest corpus of chemical reaction data ever assembled. Its contribution lies not only in sheer volume but in the systematic design that ensures comparable experimental conditions, making cross-reaction analysis scientifically meaningful. Such structured datasets enable the identification of general ligands and mechanistic diversity, revealing subtle influences on reaction efficiency, selectivity, and scalability. According to Cernak, the platform embodies over a decade of effort and technological innovation, yet it still represents the initial phase of a much broader vision to catalog and democratize chemical reaction knowledge.

This open-access data repository integrates with the broader Open Reaction Database, a growing ecosystem for sharing chemical reaction information. By making the data freely available, the project accelerates collaborative discovery, allowing researchers worldwide to perform data mining, validate models, and design experiments with previously unattainable precision. The dataset’s granularity and breadth are poised to fuel the next generation of machine learning models, which could dramatically shorten drug development timelines and reduce costs.

The study published in the Journal of the American Chemical Society rigorously compares catalytic performances of palladium, nickel, and copper under controlled experimental variations. Palladium, entrenched as the go-to catalyst for many C–N coupling reactions, often presents a procurement challenge due to geopolitical factors controlling its supply. Intriguingly, the data revealed instances where nickel and copper catalysts matched or even exceeded palladium’s performance, hinting at affordable and abundant alternatives that could revolutionize synthesis strategies in pharmaceutical manufacturing.

One of the most fascinating insights revealed by this extensive dataset was the unexpected formation of highly reactive intermediates known as arynes at surprisingly low temperatures—an observation difficult to capture with conventional reaction scope studies. Such mechanistic revelations open avenues for designing synthetic routes devoid of precious metal catalysts, a milestone with profound implications for sustainability and innovation in medicinal chemistry. The systematic scale and design of the dataset were instrumental in surfacing these insights, underscoring the value of big data approaches in chemical science.

Beyond the experimental and catalytic findings, the data-driven approach enables researchers to refine predictive models that bridge gaps between reaction conditions and synthetic feasibility. This computational foresight can guide chemists toward reaction pathways that minimize resource-intensive or environmentally harmful steps, aligning chemical synthesis with green chemistry principles. Additionally, having a centralized, searchable database can accelerate troubleshooting and reproducibility, chronic challenges in organic synthesis labs around the globe.

Timothy Cernak emphasizes that the sophistication of contemporary drugs demands increasingly complex synthetic routes. At the same time, potential vulnerabilities in metal supply chains pose tangible risks to the pharmaceutical industry. This juxtaposition highlights an urgent need for innovative tools and datasets that can fuel robust AI models, ultimately yielding safer, faster, and more cost-effective pharmaceuticals. This database project, therefore, is not only a milestone in chemical informatics but a critical infrastructure supporting global health innovation.

As this dataset continues to grow, so too does its potential to catalyze breakthroughs beyond just drug synthesis. The methodologies developed could be adapted for other classes of reactions, broadening the impact to materials science, agrochemicals, and beyond. The vision is a future where automated labs, informed by AI-powered insight fed from massive reaction datasets, can design, optimize, and produce new molecules at unprecedented scales and speeds.

Cernak’s work also exemplifies how open science can invigorate fields traditionally guarded by proprietary barriers. By democratizing access to high-quality experiment data, the chemistry community can foster a new era of transparency and collaboration—a necessary evolution in a field tasked with solving some of humanity’s most pressing challenges. This data-sharing ethos redefines how knowledge is created and disseminated, accelerating progress in ways traditional publication formats alone cannot achieve.

In conclusion, the University of Michigan’s landmark contribution of a 50,688-reaction dataset sets a transformative precedent in medicinal chemistry and synthetic methodology. By bridging the data chasm that limits AI in chemistry, it paves the way for smarter, faster, and more sustainable drug discovery pipelines. As researchers worldwide begin to mine this treasure trove, we may soon witness breakthroughs not only in pharmaceutical innovation but in the broader application of chemistry to create a healthier, more sustainable future.

Subject of Research: Cells

Article Title: A 50,688-Reaction Data Set Reveals General Ligands and Mechanistic Diversity in C–N Couplings

News Publication Date: 17-Jun-2026

Web References:

• Journal of the American Chemical Society Study (DOI: 10.1021/jacs.6c05959)
• Open Reaction Database

References:

• Cernak et al., “A 50,688-Reaction Data Set Reveals General Ligands and Mechanistic Diversity in C–N Couplings,” Journal of the American Chemical Society, 2026.

Keywords: Drug discovery, chemical synthesis, catalysis, palladium, nickel, copper, carbon-nitrogen bonds, open-access database, artificial intelligence, machine learning, medicinal chemistry, synthetic methodology

Recently, novel oral antibiotics such as zoliflodacin and gepotidacin have emerged, representing the first new classes of antibiotics to treat uncomplicated urogenital gonorrhea in more than three decades. These drugs, however, are not impervious to the adaptive prowess of N. gonorrhoeae; historical trends suggest resistance often surfaces within 5 to 10 years of widespread use. This evolutionary arms race underscores the urgent demand for continuous antibiotic innovation to replenish the drug development pipeline and maintain clinical efficacy against this resilient pathogen.

A pioneering study published in Science Translational Medicine introduces a machine learning-driven approach to antibiotic discovery tailored specifically against N. gonorrhoeae. Spearheaded by Dr. James Collins at the Wyss Institute for Biologically Inspired Engineering, Harvard University, MIT, and the Broad Institute, the research team harnessed deep learning algorithms to probe vast chemical libraries for compounds exhibiting novel antimicrobial activities. The hypothesis rested on the premise that unconventional chemical structures, which could target rare or previously unexplored bacterial pathways, might reduce the likelihood of resistance development.

To establish a functional predictive model, the researchers initially screened a comprehensive set of approximately 38,650 small molecules for their inhibitory effects on N. gonorrhoeae growth in vitro. This assay data trained a deep learning platform capable of discerning chemical features predictive of anti-gonococcal activity, going beyond structural similarities to existing antibiotics. Validation experiments confirmed the model’s ability to identify drug-like molecules with antibacterial potential, including compounds structurally distinct from the conventional antibiotic classes.

Subsequent in silico screening extended to an expansive virtual chemical library comprising roughly six million candidates. From this virtual screening emerged 213 promising compounds, which underwent rigorous in vitro growth inhibition assays and toxicity evaluations. This filtering process ultimately highlighted two compounds exhibiting pronounced selectivity and strong inhibitory potency against multidrug-resistant N. gonorrhoeae strains. Remarkably, these compounds also showed low frequencies of resistance emergence, indicating durable antimicrobial efficacy.

Delving deeper into the mechanism of action, proteomic analyses revealed that the most promising compound, designated A1, is an aminothiazole derivative with a novel target: alanine racemase. This enzyme catalyzes the conversion of L-alanine to D-alanine, an essential precursor in bacterial peptidoglycan cell wall biosynthesis. Inhibiting alanine racemase disrupts cell wall construction, compromising bacterial integrity. While cell wall biosynthesis inhibition is a known antibiotic strategy, direct targeting of alanine racemase by a small molecule is unprecedented, representing an innovative therapeutic avenue against gonorrhea.

With these encouraging molecular insights, the study progressed to physiological assessments of antimicrobial efficacy within human-relevant tissue contexts. Utilizing a microfluidic Organ Chip model of the human vagina—developed by co-author Donald Ingber’s team—the researchers simulated the natural infection environment. They demonstrated that MP20, one of the lead compounds, significantly reduced N. gonorrhoeae colonization on vaginal epithelial cells within this engineered system. Complementing this, murine vaginal infection models validated the in vivo potential of the alanine racemase inhibitor A1, where intravaginal administration led to a marked decrease in bacterial burden over multiple treatments within 24 hours.

Despite these promising preclinical findings, the authors emphasize the need for further medicinal chemistry optimization and detailed mechanistic studies to refine compound efficacy, pharmacokinetics, and safety profiles before clinical translation. The deep learning-guided discovery platform, however, signals a powerful paradigm shift—integrating artificial intelligence with high-quality biological datasets and human-relevant models to accelerate antibiotic innovation.

This research also exemplifies broader trends at the interface of computational biology, chemical sciences, and tissue engineering, where AI-driven approaches unlock vast chemical spaces previously inaccessible through conventional methodologies. The ability to rapidly identify and characterize wholly novel bioactive compounds raises the prospect of staying ahead in the persistent battle against antimicrobial resistance.

Supported by a collaborative network including the Defense Threat Reduction Agency, National Institutes of Health, Swiss and Swedish research foundations, and philanthropic entities such as the Bill and Melinda Gates Foundation, this interdisciplinary study underscores the critical role of sustained funding and cross-sector partnerships in addressing urgent global health crises.

In closing, the convergence of machine learning with advanced human tissue models offers a beacon of hope in the fight against drug-resistant pathogens like Neisseria gonorrhoeae. As resistance dynamics continue to outpace traditional drug development, such integrative and innovative approaches stand poised to redefine antibiotic discovery and herald a new frontier in infectious disease therapeutics.

Subject of Research: Animals

Article Title: Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae

News Publication Date: 17-Jun-2026

Web References:

• Wyss Institute at Harvard University
• Science Translational Medicine Journal

References:

• Valeri, J., Modaresi, M., Anahtar, M., Collins, J. et al. Deep learning-enabled discovery of antibiotics effective against Neisseria gonorrhoeae. Science Translational Medicine (2026).

Image Credits: Wyss Institute for Biologically Inspired Engineering at Harvard University

Keywords

Machine learning, Artificial intelligence, Sexually transmitted diseases, Infectious diseases, Antibiotic resistance, Antibiotic activity, Computational biology, Vagina, Mouse models, Tissue engineering, Chemical compounds, Bioactive compounds, Chemical modeling, Computational chemistry, Antibiotics

The launch of the SCW75 corresponds with a period of unprecedented growth and investment in scientific computing infrastructure. Market analyses reveal that the expenditure on accelerated and high-performance infrastructure dedicated to AI workloads surged to an astonishing $193 billion in 2024, marking a 121% year-over-year increase. Projections from Hyperion Research estimate that the broader market encompassing HPC, AI, and technical computing will eclipse $100 billion by 2028. Zhavoronkov’s recognition amidst such a competitive and impactful arena emphasizes his relentless dedication to integrating complex computational methods with biological and chemical problem-solving.

Zhavoronkov’s journey from semiconductors to biotechnology is emblematic of strategic foresight coupled with personal conviction. Having garnered significant success in the GPU industry in the early 2000s, he deliberately pivoted away from pure hardware development to focus on extending healthy human lifespans—a mission that marries cutting-edge technology with fundamental human health. This transition reflects a broader trend toward the application of AI in understanding and addressing age-related diseases, positioning Insilico Medicine at the forefront of longevity science.

Under Zhavoronkov’s visionary leadership, Insilico Medicine has architected a dual therapeutic strategy that targets both age-related diseases and the underlying biological pathways contributing to the aging process itself. By honing in on molecular pathways implicated in specific diseases as well as generalized aging mechanisms, the company ensures that its interventions yield both immediate health benefits and long-term impacts on aging. This approach not only advances the scientific frontier but also offers pragmatic solutions for pressing medical needs.

Central to Insilico’s groundbreaking drug discovery success is the Pharma.AI platform, an integrated suite that epitomizes the fusion of machine learning, vast data analytics, and computational modeling. Consisting of Biology42 for target discovery, Chemistry42 for molecular design, and Medicine42 for clinical insights, the platform compresses traditional drug discovery timelines drastically. Through automated target identification and precise molecular design, Insilico Medicine accelerates candidate progression from concept to clinical evaluation faster than conventional methodologies.

The company has showcased remarkable throughput, advancing 30 developmental candidates since 2021, with 13 assets currently undergoing clinical trials including Phase I and Phase II evaluations. These numbers signal a paradigm shift in drug development efficiency, fueled by AI-driven insights and computational power. Looking forward, Insilico aims to nominate 40 to 50 preclinical candidates within the next 24 to 36 months and to complete the industry’s first Phase III trial for a therapeutic discovered entirely through AI—a milestone that could redefine drug development’s future.

While the core focus remains on human health, Zhavoronkov envisions the transformative potential of scientific computing extending well beyond medicine. Through key partnerships, notably with Saudi Aramco, Insilico Medicine is deploying its molecular design expertise to address global sustainability challenges. Efforts in carbon capture, hydrogen storage, and the creation of clean synthetic fuels illustrate a commitment to leveraging AI-powered biotechnology for environmental innovation, further broadening the company’s impact.

Zhavoronkov’s philosophical perspective on the integration of digital and biological realms underscores a critical challenge in the field: the experimental validation of computational predictions in living systems. He contends that bridging this divide represents the defining scientific computing hurdle in healthcare, stressing the importance of rigorous biological validation alongside computational modeling. His advice to early-career researchers—to combine smarter work with greater diligence—reflects the discipline needed to achieve meaningful medical breakthroughs.

Insilico Medicine’s pioneering work rests on a robust foundation of peer-reviewed excellence and prolific academic contributions. Zhavoronkov himself is a highly cited figure, boasting over 24,000 citations and a notable h-index of 76, reflecting the impact of his research across computational biology and drug discovery. Recent high-profile publications in Nature Medicine and Nature Biotechnology detail revolutionary advances, including AI-discovered TNIK inhibitors for idiopathic pulmonary fibrosis and quantum-computing-enhanced algorithms identifying KRAS inhibitors, highlighting the practical success of AI-augmented therapeutics.

Among Insilico’s flagship candidates, Rentosertib (ISM001-055) stands out as a first-in-class small molecule inhibitor targeting the TNIK kinase implicated in fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Rentosertib has demonstrated promising results in Phase I and Phase II trials, representing one of the first drugs discovered using generative AI technologies to advance into late-stage clinical development. Such progress validates the Pharma.AI platform’s capability to translate computational designs into clinically relevant therapies.

In parallel to drug discovery, Insilico’s multidimensional approach addresses a spectrum of unmet therapeutic needs, spanning fibrosis, oncology, immunology, pain management, obesity, and metabolic disorders. By expanding the scope of AI-driven drug development, the company also explores applications in age-related diseases, positioning itself at the intersection of longevity science and precision medicine. This broad therapeutic exploration enhances the company’s pipeline resilience and potential societal impact.

Beyond human therapeutics, Insilico extends its AI platform into other industrial sectors, including advanced materials, agriculture, nutritional products, and veterinary medicine. The cross-industry applicability underscores the versatility and transformative potential of AI-driven molecular design. This strategic diversification not only strengthens Insilico’s business model but also accelerates innovation across critical sectors related to human well-being and environmental sustainability.

Insilico Medicine’s evolution into a publicly listed entity on the Hong Kong Stock Exchange in December 2025 cements its status as a global leader in AI-driven biotechnology. The company’s trajectory illustrates how the integration of advanced computational power and domain expertise can revolutionize drug discovery and longevity research. As Zhavoronkov and his team continue to pioneer new frontiers, their work serves as a beacon for the future of healthcare and scientific computing.

Subject of Research: AI-driven drug discovery and longevity research focusing on aging and age-related diseases using high-performance computing platforms.

Article Title: Alex Zhavoronkov Named to Inaugural SCW75 List for Pioneering AI-Driven Longevity Research

News Publication Date: June 4, 2026

Web References:

• https://www.scientific-computing.com/article/alex-zhavoronkov?check_logged_in=1
• https://www.insilico.com/
• https://03696.hk/

References:

• Nature Medicine (2025): “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”
• Nature Biotechnology (2024): “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models”
• Nature Biotechnology (2025): “Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors”
• Nature Communications (2025): “A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro”
• Nature Communications (2025): “Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors”

Image Credits: Insilico Medicine

Keywords: Artificial Intelligence, Drug Discovery, Longevity Research, High-Performance Computing, Generative AI, Pharma.AI, Aging, Idiopathic Pulmonary Fibrosis, Biotechnology, Molecular Design, Clinical Trials, Scientific Computing